|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.655 USD | -8.06% |
|
+4.05% | -19.64% |
| Jun. 02 | Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer | CI |
| May. 15 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -120.86 | -34.26 | -20.18 | -25.87 | -26.56 | ||
Return on Total Capital | -173.63 | -35.71 | -20.97 | -27.85 | -29.06 | ||
Return On Equity % | -299.86 | -55.7 | -30.22 | -41.2 | -43.17 | ||
Return on Common Equity | -299.86 | 2.69 | 3.22 | 5.83 | 6.88 | ||
Margin Analysis | |||||||
Gross Profit Margin % | - | - | - | 100 | 100 | ||
SG&A Margin | - | - | - | 66.79K | 5.8K | ||
EBITDA Margin % | - | - | - | -228K | -17.74K | ||
EBITA Margin % | - | - | - | -235K | -18.48K | ||
EBIT Margin % | - | - | - | -235K | -18.48K | ||
Income From Continuing Operations Margin % | - | - | - | -215K | -16.98K | ||
Net Income Margin % | - | - | - | -80.51K | -7.73K | ||
Net Avail. For Common Margin % | - | - | - | -80.51K | -7.73K | ||
Normalized Net Income Margin | - | - | - | 3.97K | -1.33K | ||
Levered Free Cash Flow Margin | - | - | - | -160K | -7.31K | ||
Unlevered Free Cash Flow Margin | - | - | - | -160K | -7.31K | ||
Asset Turnover | |||||||
Asset Turnover | - | - | - | 0 | 0 | ||
Fixed Assets Turnover | - | - | - | 0 | 0.02 | ||
Short Term Liquidity | |||||||
Current Ratio | 2.21 | 46.42 | 14.94 | 10.93 | 9.13 | ||
Quick Ratio | 1.67 | 45.09 | 14.55 | 9.96 | 8.82 | ||
Operating Cash Flow to Current Liabilities | -4.08 | -7.09 | -3.6 | -3.49 | -3.91 | ||
Long Term Solvency | |||||||
Total Debt/Equity | 4.96 | 0.48 | 1.13 | 0.81 | 1.34 | ||
Total Debt / Total Capital | 4.72 | 0.47 | 1.12 | 0.8 | 1.32 | ||
LT Debt/Equity | 3.96 | 0.38 | 0.92 | 0.62 | 0.99 | ||
Long-Term Debt / Total Capital | 3.78 | 0.38 | 0.91 | 0.61 | 0.97 | ||
Total Liabilities / Total Assets | 33.21 | 2.52 | 6.95 | 8.94 | 10.36 | ||
EBIT / Interest Expense | - | -711.66 | -12.63K | -19.82K | -41.25K | ||
EBITDA / Interest Expense | - | -694.98 | -12.22K | -18.99K | -39.29K | ||
(EBITDA - Capex) / Interest Expense | - | -703.56 | -15.07K | -22.27K | -43.09K | ||
Total Debt / EBITDA | -0.03 | -0.02 | -0.03 | -0.02 | -0.03 | ||
Net Debt / EBITDA | 0.36 | 3.26 | 2.45 | 2.08 | 1.69 | ||
Total Debt / (EBITDA - Capex) | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | ||
Net Debt / (EBITDA - Capex) | 0.33 | 3.23 | 1.98 | 1.77 | 1.54 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | - | - | - | - | 1.08K | ||
Gross Profit, 1 Yr. Growth % | - | - | - | - | 1.08K | ||
EBITDA, 1 Yr. Growth % | 103.86 | 182.29 | -1.54 | 17.1 | -8.38 | ||
EBITA, 1 Yr. Growth % | 104.77 | 178.33 | -0.97 | 17.87 | -7.48 | ||
EBIT, 1 Yr. Growth % | 103.93 | 177.64 | -0.97 | 17.71 | -7.48 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 106.16 | 168.62 | -8.57 | 20.59 | -7.18 | ||
Net Income, 1 Yr. Growth % | 106.16 | 95.9 | -67.17 | 72.51 | 12.75 | ||
Normalized Net Income, 1 Yr. Growth % | 104.25 | 50.75 | -136.73 | -84.17 | -493.35 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | 43.62 | -36.05 | 145.61 | 8.73 | -17.58 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 20.3 | 3.69 | 255.22 | -2.62 | 21.48 | ||
Total Assets, 1 Yr. Growth % | 141.31 | 1.19K | -18.81 | 4.88 | -23.92 | ||
Tangible Book Value, 1 Yr. Growth % | 187.24 | -4.24K | 0.6 | -9.83 | 1.63 | ||
Common Equity, 1 Yr. Growth % | 172.88 | -4.17K | 0.62 | -9.83 | 1.63 | ||
Cash From Operations, 1 Yr. Growth % | 99.75 | 53.26 | 16.84 | 40.28 | -4.93 | ||
Capital Expenditures, 1 Yr. Growth % | -4.84 | -64.45 | 1.75K | -13.71 | -48.5 | ||
Levered Free Cash Flow, 1 Yr. Growth % | 90.94 | -17.73 | 161.06 | 57.44 | -46.22 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | 90.94 | -18.1 | 162.23 | 57.45 | -46.22 | ||
Compound Annual Growth Rate Over Two Years | |||||||
EBITDA, 2 Yr. CAGR % | 70.42 | 139.89 | 66.72 | 7.38 | 3.58 | ||
EBITA, 2 Yr. CAGR % | 69.27 | 138.73 | 66.02 | 8.04 | 4.43 | ||
EBIT, 2 Yr. CAGR % | 69.6 | 137.95 | 65.81 | 7.97 | 4.36 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | -16.77 | 135.33 | 56.72 | 5.01 | 5.8 | ||
Net Income, 2 Yr. CAGR % | -16.77 | 100.97 | -19.8 | -24.74 | 39.46 | ||
Normalized Net Income, 2 Yr. CAGR % | 70.16 | 75.47 | -25.59 | -75.89 | -21.1 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | -39.92 | -4.17 | 25.32 | 63.42 | -5.33 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 94.63 | 11.69 | 91.92 | 85.99 | 8.76 | ||
Total Assets, 2 Yr. CAGR % | 43.36 | 456.94 | 223.05 | -7.72 | -10.67 | ||
Tangible Book Value, 2 Yr. CAGR % | 32.77 | 990.58 | 545.41 | -4.76 | -4.27 | ||
Common Equity, 2 Yr. CAGR % | 30.18 | 954.39 | 540.25 | -4.75 | -4.27 | ||
Cash From Operations, 2 Yr. CAGR % | -19.08 | 74.97 | 33.82 | 28.02 | 15.48 | ||
Capital Expenditures, 2 Yr. CAGR % | 99.46 | -41.83 | 156.64 | 299.82 | -33.34 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 25.33 | 46.55 | 102.74 | -7.98 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 25.05 | 46.55 | 103.2 | -7.98 | ||
Compound Annual Growth Rate Over Three Years | |||||||
EBITDA, 3 Yr. CAGR % | - | 101.64 | 78.28 | 48.2 | 1.85 | ||
EBITA, 3 Yr. CAGR % | - | 99.79 | 78.04 | 48.11 | 2.6 | ||
EBIT, 3 Yr. CAGR % | - | 99.88 | 77.65 | 47.92 | 2.55 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 23 | 71.72 | 43.61 | 0.78 | ||
Net Income, 3 Yr. CAGR % | - | 10.71 | 9.86 | 3.53 | -13.89 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 63.43 | 4.19 | -55.58 | -38.85 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | -38.66 | 31.15 | 19.53 | 30.08 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 57.78 | 64.25 | 53.07 | 61.37 | ||
Total Assets, 3 Yr. CAGR % | - | 197.83 | 193.11 | 122.03 | -13.47 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 317.93 | 392.76 | 234.9 | -2.67 | ||
Common Equity, 3 Yr. CAGR % | - | 310.24 | 381.83 | 233.11 | -2.67 | ||
Cash From Operations, 3 Yr. CAGR % | - | 0.12 | 52.93 | 35.94 | 15.93 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 12.26 | 84.38 | 78.46 | 101.91 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 60.06 | 50.1 | 30.27 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 60.06 | 50.09 | 30.46 | ||
Compound Annual Growth Rate Over Five Years | |||||||
EBITDA, 5 Yr. CAGR % | - | - | - | 56.72 | 43.47 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 56.24 | 43.83 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 56.24 | 43.6 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 15.46 | 41.48 | ||
Net Income, 5 Yr. CAGR % | - | - | - | -5.13 | 20.86 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | -23.99 | -6.78 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | -9.23 | 15.12 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 68.51 | 39.28 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 86.39 | 82.23 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 131.31 | 155.86 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 128.76 | 152.44 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 10.47 | 36.68 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | 86.58 | 22.74 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 28.27 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 28.27 |
- Stock Market
- Stocks
- PROK Stock
- Financials ProKidney Corp.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















